Edition:
United States

Medicines Co (MDCO.O)

MDCO.O on Nasdaq

35.47USD
20 Jan 2017
Change (% chg)

-- (--)
Prev Close
$35.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,234,519
52-wk High
$41.79
52-wk Low
$27.50

Select another date:

Mon, Nov 28 2016

BRIEF-Mylan signs sub-license agreement with the Medicines Patent Pool to produce and market DAKLINZA tablets to 112 countries

* Mylan signs sub-license agreement with the Medicines Patent Pool to increase access to Hepatitis C treatment in developing countries

BRIEF-The Medicines Company, Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran

* The Medicines Company and Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran (formerly PCSK9si)

Long-lasting cholesterol lowering seen with Medicines Co drug: study

NEW ORLEANS A new type of heart drug developed by Medicines Co significantly lowered "bad" LDL cholesterol in high-risk patients with no major safety issues, according to data from a midstage trial that helped the company identify the dose it will move into advanced testing.

Long-lasting cholesterol lowering seen with Medicines Co drug -study

NEW ORLEANS, Nov 15 A new type of heart drug developed by Medicines Co significantly lowered "bad" LDL cholesterol in high-risk patients with no major safety issues, according to data from a midstage trial that helped the company identify the dose it will move into advanced testing.

BRIEF-Alnylam Pharmaceuticals, Medicines Co announce publication of Phase 1 Clinical Data with Inclisiran

* Results from study showed doses 300 mg significantly reduced pcsk9 and ldl cholesterol for at least 6 months

BRIEF-Medicines Co says discontinues development of MDCO-216

* Medicines Co says discontinues development of MDCO-216, its investigational cholesterol efflux promoter

BRIEF-Medicines Q3 revenue $37.6 mln versus I/B/E/S view $37.3 mln

* The medicines company reports third-quarter 2016 financial results

BRIEF-China National Accord Medicines to buy 30 pct stake in unit at 3.5 mln yuan

* Says it plans to acquire 30 percent stake in its 70 percent owned unit, at price of 3.5 million yuan

BRIEF-Medicines Co announces positive top-line results from day 90 interim analysis in ongoing Orion-1 Phase 2 study of PCSK9si

* Medicines company announces positive top-line results from day 90 interim analysis in ongoing orion-1 phase 2 study of pcsk9si

BRIEF-The Medicines Company says provides update on PCSK9si study

Oct 5 The Medicines Company Provides Progress Update On Ongoing Orion

Select another date: